Kyorin And Hinge Bio Enter Into A Collaboration And License Agreement Of Hb2198 In Japan For Sle And Other Diseases

Kyorin Pharmaceutical

01/10/2025 24:33

Oct 1 (Reuters) - Kyorin Pharmaceutical Co Ltd 4569.T:

KYORIN PHARMACEUTICAL CO LTD: KYORIN AND HINGE BIO ENTER INTO A COLLABORATION AND LICENSE AGREEMENT OF HB2198 IN JAPAN FOR SLE AND OTHER DISEASES

KYORIN PHARMACEUTICAL CO LTD: IMPACT ON CONSOLIDATED EARNINGS FORECAST FOR FISCAL YEAR ENDING MARCH 2026 IS EXPECTED TO INCLUDE UPFRONT PAYMENT TO HINGE BIO UNDER THIS AGREEMENT, WHICH WILL BE RECORDED AS SG&A EXPENSES (RESEARCH AND DEVELOPMENT EXPENSES) FOR CURRENT FISCAL YEAR

Source text: ID:nTSud8a1f0

Further company coverage: 4569.T

 (Reporting by Tokyo Newsroom)

 ((+81345201189;))